Our flyers offer insight into selected groups of products in peptide and oligonucleotide research.
alpha-Methyl Amino Acids
Bachem’s portfolio of α-methyl amino acids has been extended by a set of new innovative products, produced by our partner DOTTIKON Exclusive Synthesis AG. α-Methyl amino acids can be obtained by various methods such as Cα-methylation of N,N-disubstituted amino acid derivatives in the presence of a chiral catalyst. The proprietary approach of Maruoka et al. starting from N-p-chlorobenzylidene amino acid esters is especially suited for the modification of aromatic amino acids. A biphenyl-derived chiral phase-transfer catalyst promotes enantioselective alkylation.
Commerical Peptide NCE
Benefit from innovation, expertise and cutting-edge equipment that fits your needs from small to large-scale and from a GMP environment to develop and commercialize your peptide API therapeutic! With our operational excellence and customer-centric approach, we offer a clear Chemistry, Manufacturing and Control (CMC) plan for your project. Benefit from our technological leadership and innovation for higher
quality, capacity and sustainability.
Impurites in Peptides APIs
Impurities observed in peptide APIs can be process related impurities, which cannot be removed completely during purification of the crude peptide or product related impurities that are formed as degradation products during storage. Typically these impurities are byproducts resulting from side reactions occurring during the syntheses, such as racemization, deamidation, oxidation or aspartimide formation. Peptide APIs obtained by solid-phase synthesis may additionally contain analogs resulting from deletion or double insertion of amino acids. References of such compounds are needed for analytical method development and release testing, because fulfilling the specifications for byproducts is required by the relevant pharmacopeia and, most importantly, for ensuring the quality of the API.
Lanreotide
The long-acting somatostatin agonist Lanreotide (INN) was initially developed for the management of acromegaly, for which it has been approved in many countries. Consecutive studies showed that lanreotide alleviates symptoms caused by neuroendocrine tumors, most notably carcinoid syndrome, and can serve as an alternative to octreotide in this field. Interestingly, lanreotide also shows activity against non-endocrine tumors, and, along with other somatostatin analogs, is being studied as a possible general anti-tumor agent.
Oligonucleotide therapeutics
The potential of oligonucleotide based drugs is finally receiving the focus it deserves. You can count on Bachem to bring a new level of innovation to help transform the lives of our customers and ultimately of patients.
Oligonucleotide therapeutics – Chinese
The potential of oligonucleotide based drugs is finally receiving the focus it deserves. You can count on Bachem to bring a new level of innovation to help transform the lives of our customers and ultimately of patients.
Oligonucleotide therapeutics – Japanese
The potential of oligonucleotide based drugs is finally receiving the focus it deserves. You can count on Bachem to bring a new level of innovation to help transform the lives of our customers and ultimately of patients.
Oligonucleotide therapeutics – Korean
The potential of oligonucleotide based drugs is finally receiving the focus it deserves. You can count on Bachem to bring a new level of innovation to help transform the lives of our customers and ultimately of patients.
Oligonucleotides APIs Microsynth
Several antisense oligonucleotide drugs have been approved by the regulatory agencies (FDA, EMEA) in the past two decades. Oligonucleotide-based therapeutics generally are a hot topic in research and development as they open the door for the treatment of a broad range of diseases that cannot be treated differently. Two pioneers in the industry, Microsynth AG and Bachem AG, with long-term experience in catering to the phamaceutical industry as well as research organizations, offer the full portfolio of services and products needed to successfully develop, launch and market oligonucleotide APIs.
Periodic Chart of Amino Acids
Our ‘Periodic Chart of Amino Acids’ gives you a short overview on the 20 proteinogenic amino acids, the common Fmoc- and Boc-strategy solid phase peptide synthesis (SPPS) protecting groups, and the absorption and emission characteristics of chromophores and fluorophores.
Periodic Chart of Unusual Alpha-Amino Acids
Our ‘Periodic Chart of Unusual α-Amino Acids’ lists a large selection of unusual α-amino acids and there commonly used abbreviations.
Teplow’s Peptides
Our new partner, the Teplow laboratory seeks to understand and treat diseases associated with the aging process. Teplow’s Amyloid β-Protein (1-42) and Teplow’s Amyloid β-Protein (1-40), our “Teplow`s Peptides”, are new negative control peptides, designed by the Teplow laboratory for studies towards the aggregation behavior of Aβ.
You Can Focus on your Masterpiece
We take care of everything else. Bachem in commercial generics.
